Search Results for "Everolimus Thymus Cancer"
Original Source: Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving lapatinib together with everolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and everolimus in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
Matching Channels
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated...
Ovarian cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian cancer are those who have had fe...
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common ca...
Matching News
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
(European Society for Medical Oncology) A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab showed a statistically n...
Everolimus Can Overcome Trastuzumab Resistance In HER-2 Positive Early Breast Cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a...
Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, i...
Advanced Breast Cancer Patients Denied Access To Breakthrough Treatment
National Institute for Health and Clinical Excellence (NICE) issues negative draft decision for Afinitor® (everolimus) The National Institute for Health and Clinical Excellence (NICE) today issued an...
Optimal dosing of everolimus defined for advanced liver cancer
NEW YORK (Reuters Health) - Everolimus was more effective when given daily rather than weekly to patients with advanced hepatocellular cancer (HCC), and the maximum tolerated dose was 7.5 mg/day,...
Adjuvant Everolimus for Resected Kidney Cancer
In this clinical trial, patients with renal cell cancer who have undergone partial or complete nephrectomy will be randomly assigned to take everolimus tablets or matching placebo tablets daily for 54...
Afinitor (Everolimus) Combo For Breast Cancer Approved By FDA
The FDA has approved Afinitor (everolimus) in combination with Aromasin (exemestane) for the treatment of some postmenopausal females with advanced hormone-receptor positive, HER2-negative breast canc...
Matching PubMed Articles
The growth potential of PC3 prostate cancer cells, sensible (PC3(par)) or resistant (PC3(res)) to the mTOR inhibitor everolimus (RAD001) was investigated. Cell growth and proliferation of PC3(res) was...
PURPOSE: Everolimus is a novel inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in cancer cell. We conducted a phase I study of capecitabine plus everolimus (RAD00...
Everolimus for the treatment of advanced renal cell carcinoma.
Introduction: The efficacy of sequential everolimus (RAD001, Afinitor®), an orally administered inhibitor of mammalian target of rapamycin (mTOR), is one of the therapeutic options in patients with a...
Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol 3-kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth and metabolism. Dys...
Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamyc...
